Aptamer Group deserve more attention 

Aptamer Group (LSE: APTA) are unchanged at 0.325p with a £11.7m mkt cap after reporting finals to June 2026 showing significant commercial traction. Over the last three months, the sales pipeline increased 46% from the end of June to £7.0m in September. Revenue for the FY June 26 improved 28% to £1.5m and the EBITDA loss marginally rose to £2.3m from £2.2m, as administration expenses increased to £3.2m from £2.9m as a result of the increased activity. Aptamer is strategically focused on by targeting "undruggable" proteins and enabling delivery of therapeutics to tissues beyond the liver. Its p...

Latest News

More Articles Like This